Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors

Taner Demirer, Lisbeth Barkholt, Didier Blaise, Paolo Pedrazzoli, Massimo Aglietta, Angelo Michele Carella, Jacques Olivier Bay, Fikret Arpaci, Giovanni Rosti, Gunhan Gurman, Dietger Niederwieser, Marco Bregni

Research output: Contribution to journalArticle

Abstract

Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an immune graft-versus-tumor (GVT) effect mediated by donor lymphocytes. The development of nonmyeloablative conditioning regimens before allogeneic transplantation has allowed this therapy to be used in elderly and disabled patients. An allogeneic GVT effect is observed in a proportion of patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with allogeneic transplantation. In general, the tumor response is associated with the development of acute and chronic graft-versus-host disease. Further improvements will depend on the identification of the antigen targets of GVT, and on reduction of the toxicity of the procedure. Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party.

Original languageEnglish
Pages (from-to)256-267
Number of pages12
JournalNature Clinical Practice Oncology
Volume5
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Neoplasms
Transplants
Tissue Donors
Therapeutics
Kidney Neoplasms
Immune System Diseases
Graft vs Host Disease
Hematologic Neoplasms
Bone Marrow Transplantation
Pancreatic Neoplasms
Ovarian Neoplasms
Colorectal Neoplasms
Bone Marrow
Lymphocytes
Breast Neoplasms
Antigens

ASJC Scopus subject areas

  • Oncology

Cite this

Transplantation of allogeneic hematopoietic stem cells : An emerging treatment modality for solid tumors. / Demirer, Taner; Barkholt, Lisbeth; Blaise, Didier; Pedrazzoli, Paolo; Aglietta, Massimo; Carella, Angelo Michele; Bay, Jacques Olivier; Arpaci, Fikret; Rosti, Giovanni; Gurman, Gunhan; Niederwieser, Dietger; Bregni, Marco.

In: Nature Clinical Practice Oncology, Vol. 5, No. 5, 05.2008, p. 256-267.

Research output: Contribution to journalArticle

Demirer, T, Barkholt, L, Blaise, D, Pedrazzoli, P, Aglietta, M, Carella, AM, Bay, JO, Arpaci, F, Rosti, G, Gurman, G, Niederwieser, D & Bregni, M 2008, 'Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors', Nature Clinical Practice Oncology, vol. 5, no. 5, pp. 256-267. https://doi.org/10.1038/ncponc1104
Demirer, Taner ; Barkholt, Lisbeth ; Blaise, Didier ; Pedrazzoli, Paolo ; Aglietta, Massimo ; Carella, Angelo Michele ; Bay, Jacques Olivier ; Arpaci, Fikret ; Rosti, Giovanni ; Gurman, Gunhan ; Niederwieser, Dietger ; Bregni, Marco. / Transplantation of allogeneic hematopoietic stem cells : An emerging treatment modality for solid tumors. In: Nature Clinical Practice Oncology. 2008 ; Vol. 5, No. 5. pp. 256-267.
@article{09f68a6d672e4bf69d1789896dbd20e4,
title = "Transplantation of allogeneic hematopoietic stem cells: An emerging treatment modality for solid tumors",
abstract = "Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an immune graft-versus-tumor (GVT) effect mediated by donor lymphocytes. The development of nonmyeloablative conditioning regimens before allogeneic transplantation has allowed this therapy to be used in elderly and disabled patients. An allogeneic GVT effect is observed in a proportion of patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with allogeneic transplantation. In general, the tumor response is associated with the development of acute and chronic graft-versus-host disease. Further improvements will depend on the identification of the antigen targets of GVT, and on reduction of the toxicity of the procedure. Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party.",
author = "Taner Demirer and Lisbeth Barkholt and Didier Blaise and Paolo Pedrazzoli and Massimo Aglietta and Carella, {Angelo Michele} and Bay, {Jacques Olivier} and Fikret Arpaci and Giovanni Rosti and Gunhan Gurman and Dietger Niederwieser and Marco Bregni",
year = "2008",
month = "5",
doi = "10.1038/ncponc1104",
language = "English",
volume = "5",
pages = "256--267",
journal = "Nature Clinical Practice Oncology",
issn = "1743-4254",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Transplantation of allogeneic hematopoietic stem cells

T2 - An emerging treatment modality for solid tumors

AU - Demirer, Taner

AU - Barkholt, Lisbeth

AU - Blaise, Didier

AU - Pedrazzoli, Paolo

AU - Aglietta, Massimo

AU - Carella, Angelo Michele

AU - Bay, Jacques Olivier

AU - Arpaci, Fikret

AU - Rosti, Giovanni

AU - Gurman, Gunhan

AU - Niederwieser, Dietger

AU - Bregni, Marco

PY - 2008/5

Y1 - 2008/5

N2 - Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an immune graft-versus-tumor (GVT) effect mediated by donor lymphocytes. The development of nonmyeloablative conditioning regimens before allogeneic transplantation has allowed this therapy to be used in elderly and disabled patients. An allogeneic GVT effect is observed in a proportion of patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with allogeneic transplantation. In general, the tumor response is associated with the development of acute and chronic graft-versus-host disease. Further improvements will depend on the identification of the antigen targets of GVT, and on reduction of the toxicity of the procedure. Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party.

AB - Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an immune graft-versus-tumor (GVT) effect mediated by donor lymphocytes. The development of nonmyeloablative conditioning regimens before allogeneic transplantation has allowed this therapy to be used in elderly and disabled patients. An allogeneic GVT effect is observed in a proportion of patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with allogeneic transplantation. In general, the tumor response is associated with the development of acute and chronic graft-versus-host disease. Further improvements will depend on the identification of the antigen targets of GVT, and on reduction of the toxicity of the procedure. Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party.

UR - http://www.scopus.com/inward/record.url?scp=42649104036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42649104036&partnerID=8YFLogxK

U2 - 10.1038/ncponc1104

DO - 10.1038/ncponc1104

M3 - Article

C2 - 18398414

AN - SCOPUS:42649104036

VL - 5

SP - 256

EP - 267

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1743-4254

IS - 5

ER -